clinical trial · NCT07392255
An Optimised GA Interventional Trial (Opti-GAIN) to Test if Treatment With CTx001 is Safe and Works for People With Geographic Atrophy (GA)
Geographic Atrophy Secondary to Age-related Macular DegenerationCTx001
brief summary
This is a clinical study to evaluate the safety, tolerability and efficacy of CTx001, administered via a single subretinal injection, for GA (secondary to AMD). Safety and efficacy will be measured at regular intervals for 2 years after which long-term safety will be assessed annually for up to 5 years.
started
Dec 30, 2025
primary completion
May 31, 2028
completion
Jun 30, 2032
last updated
Mar 17, 2026
official title
A First in Human Phase 1 / 2 Multi-center Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of CTx001 Administered Via a Single Subretinal Injection in Patients With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol